Endocrinology and Diabetes
The main focus of the Endocrinology and Diabetes Research team is osteoporosis, a disease affecting over one million Australians that makes bones become brittle leading to a higher risk of breaks than in normal bone.
Much of our research uses data from the Geelong Osteoporosis Study, as well as clinical data gathered through our clinical practices. Recent analyses have focused on muscle loss, frailty and the effect of diabetes on the skeleton. In collaboration with Barwon Health's Intensive Care Unit, we are also examining the impact of critical illness on skeletal health and mortality.
Our Endocrinology Clinical Trial Unit (CTU) undertakes clinical trials in disorders of bone and calcium as well as diabetes and obesity-related studies. The CTU is the Australian lead site for a study of early intervention in Paget’s disease of bone as well as studies examining new therapeutics in the management of diabetes. The CTU is national lead on the majority of its commercially sponsored clinical trials and is renowned for its start-up timelines.
|Lausanne University Hospital, Switzerland||Active Life Sciences, California|
|University of Edinburgh, Western General Hospital||Westmead Hospital|
|Monash Health||Hudson Institute of Medical Research|
- Professor Mark Kotowicz, Director
- Dr Shannon McCarthy, Clinical Trial Principal Investigator
- Dr Aaron Choy, Endocrine Fellow
- Dr Anna Anderson, Endocrine Fellow
- Alana Sarah, Clinical Trials Unit Manager
- Bree Sarah, Clinical Trials Unit Manager
- Jo Chambers, Clinical Trials Nurse Coordinator
- Kate Ellis, Clinical Trials Nurse Coordinator
- Fahriya Zandari, Clinical Trials Nurse Coordinator
- Lelia de Abreu, PhD, Glycaemia status, all-cause mortality and skeletal morbidity in women
- Monica Tembo, PhD, Biological factors that underpin frailty and musculoskeletal decline
- Matthew Thackery, MPhil, The effect of critical illness on muscle mass
Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: Position statement of the endocrine society of Australia, the Australian and New Zealand Bone & Mineral Society. Grossmann M, Ramchand SK, Milat F, Vincent A, Lim E, Kotowicz MA, Hicks J, Teede H. Clin Endocrinol (Oxf). 2018;89: 280-296.
Trabecular bone score in men and women with impaired fasting glucose and diabetes. [NOTE - Full text for Barwon Health staff; public can view abstract]. Holloway KL, De Abreu, Lelia L. F., Hans D, Kotowicz MA, Sajjad MA, Hyde NK, Pasco JA. Calcif Tissue Int. 2017;102: 32-40.
Changes in Bone Mineral Density in the Year After Critical Illness. Orford NR, Lane SE, Bailey M, Pasco JA, Cattigan C, Elderkin T, Brennan-Olsen SL, Bellomo R, Cooper DJ, Kotowicz MA. Am J Respir Crit Care Med. 2016;193(7): 736-744.
A meta-analysis of trabecular bone score in fracture risk prediction and its relationship to FRAX. McCloskey EV, Odén A, Harvey NC, Leslie WD, Hans D, Johansson H, Barkmann R, Boutroy S, Brown J, Chapurlat R, et al. J Bone Min Res. 2015;31: 940-948.
Body mass index and measures of body fat for defining obesity and underweight: A cross-sectional, population-based study. Pasco JA, Holloway KL, Dobbins AG, Kotowicz MA, Williams LJ, Brennan SL. BMC Obesity. 2014;1:9142.
Increased risk of cognitive impairment in patients with diabetes is associated with metformin. Moore EM, Mander AG, Ames D, Kotowicz MA, Carne RP, Brodaty H, Woodward M, Boundy K, Ellis KA, Bush AI, et al. Diabetes Care. 2013;36: 2981-2987.
Skeletal morbidity among survivors of critical illness. [NOTE - Full text for Barwon Health staff; public can view abstract]. Orford NR, Saunders K, Merriman E, Henry M, Pasco J, Stow P, Kotowicz M. Crit Care Med. 2011 Jun;39(6) 1295-1300.
Genome-wide association study using extreme truncate selection identifies novel genes affecting bone mineral density and fracture risk. Duncan EL, Danoy P, Kemp JP, Leo PJ, McCloskey E, Nicholson GC, Eastell R, Prince RL, Eisman JA, Jones G, et al. PLoS Genetics. 2011;7(4):e1001372.
Prevalence of osteoporosis in Australian men and women: Geelong Osteoporosis Study. [NOTE - Full text for Barwon Health staff; public can view abstract]. Henry MJ, Pasco JA, Nicholson GC, Kotowicz MA. Med J Aust 2011;195(6): 31-32.
Annual high-dose oral vitamin D and falls and fractures in older women. Sanders KM, Stuart AL, Williamson EJ, Simpson JA, Kotowicz MA, Young D, Nicholson GC. JAMA. 2010;303: 1815-1822.
Support Our Research
Participate in a Clinical Trial
To find out about clinical trials currently underway at Barwon Health, click here.
Clinical trials require ongoing investment and there are several ways to support this amazing work.
You can make a donation today and contribute to an item on our research wish list, consider a bequest in your will, or establish a lasting legacy fund in your name. No matter what size, your philanthropic support with deliver an immediate impact.
To donate now or for more information and further discuss your support, please contact the Barwon Health Foundation.
- Return economy airfare & accommodation for Dr Kara Holloway-Kew to undertake impact microindentation on 114 participants with chronic kidney disease at Westmead Hospital = $1,894
- DXA scans for 228 participants with chronic kidney disease at University Hospital Geelong and Westmead Hospital= $27,360
- Purchase of OsteoProbe RUO (Research Use Only) tips: 228 tips @ USD 100 per tip = $35,077
Last Modified: Tuesday, 22 March 2022
Professor Mark Kotowicz
Director, Department of Endocrinology and Diabetes
Phone (03) 4215 1142
Ms Bree Sarah
Clinical Trials Unit Manager
Phone (03) 4215 2875
University Hospital Geelong
Bellerine St, Geelong 3220